Search For "subject expert committee"
SEC recommends granting emergency use authorisation to Serum Institute of
Updated : 4 years, 2 months ago IST
New Delhi [India], March 4 (ANI): The Subject Expert Committee (SEC) has recommended granting emergency use authorisation (EUA) to Serum India of India's COVID-19 vaccine Covovax for the age group 12-17, said the official sources.
Read More
SEC recommends COVID-19 vaccine Corbevax for 12-18 year age group: Sources
Updated : 4 years, 3 months ago IST
New Delhi [India], February 15 (ANI): The Drugs Controller General of India (DCGI)'s Subject Expert Committee (SEC) has recommended Emergency Use Authorization to Hyderabad-based pharmaceutical company Biological E's COVID-19 vaccine, Corbevax, for the age group 12 to 18 years subject to
Read More
Subject expert committee recommends Russia's Sputnik Light one-shot COVID-
Updated : 4 years, 3 months ago IST
New Delhi [India], February 5 (ANI): The subject expert committee under India's drug regulator has recommended Russia's Sputnik Light one-shot COVID-19 vaccine, sources told ANI.
Read More
COVID-19: Nasal vaccine could be a game-changer if it provides mucosal imm
Updated : 4 years, 3 months ago IST
New Delhi [India], January 30 (ANI): As Hyderabad-based drug maker Bharat Biotech has got regulatory approval to conduct Phase-3 clinical trials of its intranasal COVID-19 vaccine as a booster dose, senior epidemiologist in All India Institute of Medical Sciences (AIIMS) in Delhi, Dr Sanjay
Read More
SEC recommends regular market approval to Covaxin, Covishield for adults
Updated : 4 years, 4 months ago IST
New Delhi [India], January 19 (ANI): The Drugs Controller General of India's (DCGI) subject expert committee (SEC) has recommended the regular market approval to Serum Institute of India and Bharat Biotech for their COVID-19 vaccines Covaxin and Covishield with conditions for the adult po
Read More
SEC asks for more data to grant full market approval to Covaxin and Covish
Updated : 4 years, 4 months ago IST
New Delhi [India], January 14 (ANI): The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) will continue thorough review of data submitted by the Serum Institute of India (SII) and Bharat Biotech for granting full market approval to Covaxin and Covishield, sources
Read More
DCGI's SEC to review applications of Bharat Biotech, SII for full market a
Updated : 4 years, 4 months ago IST
New Delhi [India], January 14 (ANI): Drugs Controller General of India (DCGI)'s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, sources said.
Read More
SEC to hold meeting on Bharat Biotech's Nasal vaccine booster dose
Updated : 4 years, 4 months ago IST
New Delhi [India], January 4 (ANI): The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) is expected to meet on Tuesday afternoon to discuss Bharat Biotech's application for clinical trials of its intranasal Covid vaccine as a booster or a third dose.
Read More
SEC recommends emergency use authorization of Covovax, Corbevax vaccines f
Updated : 4 years, 4 months ago IST
New Delhi [India], December 28 (ANI): After reviewing all applications and data, the Subject Expert Committee (SEC), a body under India's drug regulator, has recommended granting the Emergency Use Authorization (EUA) to Serum Institute of India's COVID-19 vaccine Covovax and Corbevax vacc
Read More
SEC to take decision on antiviral Covid pill today
Updated : 4 years, 4 months ago IST
New Delhi [India], December 27 (ANI): After reviewing all applications and data on antiviral pills, the Subject expert committee (SEC) a body under India's drug regulator will be meeting today for antiviral pill Molnupiravir recommendations, sources told to ANI.
Read More
No recommendations for COVID-19 booster dose by SEC: Sources
Updated : 4 years, 5 months ago IST
New Delhi [India], December 11 (ANI): The Subject Expert Committee (SEC) under Central Drugs Standard Control Organization (CDSCO) has said COVID-19 that booster doses cannot be recommended without clinical trials.
Read More
Subject Expert Committee to meet tomorrow to discuss approval for Covishie
Updated : 4 years, 5 months ago IST
New Delhi [India], December 9 (ANI): The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) will hold the first meeting on Friday regarding the COVID-19 booster dose, said sources on Thursday.
Read More